MiR‐146a‐5p correlates with clinical efficacy in patients with psoriasis treated with the tumour necrosis factor‐alpha inhibitor adalimumab

Inter-individual variability in clinical efficacy of different biological treatments in psoriatic patients, has been observed. Thus, the identification of a blood-based biomarker able to foresee the therapeutic response to treatment is urgently needed, especially considering the high cost of biological therapies. MicroRNAs (miRs) deregulation were previously observed in psoriatic patients, and increasing evidence highlighted that miRs could be novel biomarkers not only with diagnostic/prognostic relevance, but also for monitoring therapeutic response in patients with psoriasis. This article is protected by copyright. All rights reserved.